 Kavita Nair
Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Insurance, Pharmaceutical Services | 6 | 2020 | 21 | 1.690 |
Why?
| | Drugs, Generic | 3 | 2021 | 18 | 1.580 |
Why?
| | Chronic Disease | 6 | 2020 | 1637 | 1.140 |
Why?
| | Multiple Sclerosis | 4 | 2023 | 384 | 1.140 |
Why?
| | Managed Care Programs | 5 | 2011 | 135 | 1.080 |
Why?
| | Prescription Drugs | 2 | 2021 | 113 | 1.030 |
Why?
| | Choice Behavior | 2 | 2020 | 160 | 0.870 |
Why?
| | Cost Sharing | 3 | 2020 | 14 | 0.860 |
Why?
| | Insurance Benefits | 3 | 2010 | 10 | 0.820 |
Why?
| | Nervous System Diseases | 2 | 2023 | 261 | 0.810 |
Why?
| | Drug Costs | 1 | 2021 | 94 | 0.740 |
Why?
| | Health Services | 2 | 2009 | 110 | 0.630 |
Why?
| | Medicare Part D | 2 | 2021 | 25 | 0.570 |
Why?
| | Health Expenditures | 4 | 2012 | 174 | 0.570 |
Why?
| | Insurance Coverage | 2 | 2011 | 208 | 0.520 |
Why?
| | Insurance, Health | 3 | 2016 | 244 | 0.480 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2012 | 304 | 0.440 |
Why?
| | Arthritis, Gouty | 1 | 2012 | 14 | 0.430 |
Why?
| | Absenteeism | 1 | 2012 | 38 | 0.430 |
Why?
| | Gout Suppressants | 1 | 2012 | 33 | 0.430 |
Why?
| | Practice Patterns, Physicians' | 1 | 2021 | 1200 | 0.430 |
Why?
| | Health Care Costs | 2 | 2012 | 394 | 0.410 |
Why?
| | Health Resources | 1 | 2012 | 132 | 0.390 |
Why?
| | Diagnostic Tests, Routine | 1 | 2011 | 88 | 0.370 |
Why?
| | Health Benefit Plans, Employee | 1 | 2009 | 20 | 0.340 |
Why?
| | Antibodies, Monoclonal | 3 | 2012 | 1285 | 0.340 |
Why?
| | Autoimmune Diseases | 1 | 2012 | 398 | 0.340 |
Why?
| | Immunologic Factors | 1 | 2011 | 225 | 0.340 |
Why?
| | Adrenal Cortex Hormones | 1 | 2012 | 521 | 0.330 |
Why?
| | Program Development | 1 | 2010 | 357 | 0.320 |
Why?
| | Loratadine | 2 | 2005 | 3 | 0.310 |
Why?
| | Nonprescription Drugs | 2 | 2005 | 67 | 0.290 |
Why?
| | United States | 10 | 2023 | 12557 | 0.290 |
Why?
| | Antirheumatic Agents | 1 | 2009 | 254 | 0.280 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2023 | 667 | 0.270 |
Why?
| | Drug Prescriptions | 3 | 2005 | 248 | 0.260 |
Why?
| | Infusions, Intravenous | 2 | 2023 | 380 | 0.250 |
Why?
| | Dyslipidemias | 1 | 2005 | 162 | 0.240 |
Why?
| | Medicare | 1 | 2009 | 665 | 0.240 |
Why?
| | Neurology | 2 | 2023 | 94 | 0.230 |
Why?
| | Prescription Fees | 1 | 2003 | 3 | 0.230 |
Why?
| | Quality Indicators, Health Care | 1 | 2005 | 295 | 0.220 |
Why?
| | Diabetes Mellitus | 2 | 2010 | 945 | 0.220 |
Why?
| | Adult | 12 | 2023 | 31525 | 0.210 |
Why?
| | Patient Outcome Assessment | 1 | 2023 | 122 | 0.210 |
Why?
| | Information Services | 1 | 2001 | 46 | 0.200 |
Why?
| | Male | 15 | 2023 | 57818 | 0.200 |
Why?
| | Insurance Claim Review | 2 | 2012 | 67 | 0.200 |
Why?
| | Middle Aged | 11 | 2020 | 27627 | 0.200 |
Why?
| | Neurologists | 1 | 2021 | 19 | 0.200 |
Why?
| | Retrospective Studies | 8 | 2023 | 12990 | 0.190 |
Why?
| | Female | 15 | 2023 | 61588 | 0.190 |
Why?
| | Community Participation | 1 | 2001 | 120 | 0.190 |
Why?
| | Humans | 22 | 2023 | 119032 | 0.190 |
Why?
| | Infliximab | 2 | 2012 | 94 | 0.190 |
Why?
| | Arthritis, Rheumatoid | 1 | 2009 | 990 | 0.190 |
Why?
| | Dementia | 1 | 2023 | 208 | 0.190 |
Why?
| | Attitude to Health | 1 | 2003 | 410 | 0.180 |
Why?
| | Patient Satisfaction | 1 | 2003 | 610 | 0.170 |
Why?
| | Aged | 9 | 2023 | 19661 | 0.160 |
Why?
| | Pharmaceutical Services | 2 | 2011 | 79 | 0.140 |
Why?
| | Models, Statistical | 1 | 2020 | 636 | 0.140 |
Why?
| | Drug Utilization Review | 3 | 2005 | 60 | 0.130 |
Why?
| | Medication Adherence | 2 | 2010 | 556 | 0.130 |
Why?
| | Ambulatory Care | 2 | 2023 | 482 | 0.130 |
Why?
| | Formularies as Topic | 2 | 2003 | 6 | 0.120 |
Why?
| | Aged, 80 and over | 4 | 2016 | 6562 | 0.110 |
Why?
| | Young Adult | 4 | 2016 | 10799 | 0.110 |
Why?
| | Population Surveillance | 1 | 2016 | 413 | 0.110 |
Why?
| | Contraindications | 1 | 2012 | 86 | 0.110 |
Why?
| | Cohort Studies | 3 | 2013 | 5117 | 0.100 |
Why?
| | Costs and Cost Analysis | 1 | 2012 | 202 | 0.100 |
Why?
| | Mitoxantrone | 1 | 2011 | 12 | 0.100 |
Why?
| | Glatiramer Acetate | 1 | 2011 | 20 | 0.100 |
Why?
| | Age Distribution | 1 | 2012 | 362 | 0.100 |
Why?
| | Hematologic Tests | 1 | 2011 | 24 | 0.100 |
Why?
| | Natalizumab | 1 | 2011 | 46 | 0.100 |
Why?
| | Financing, Personal | 1 | 2011 | 27 | 0.100 |
Why?
| | Interferon-beta | 1 | 2011 | 82 | 0.100 |
Why?
| | Poisson Distribution | 1 | 2010 | 68 | 0.090 |
Why?
| | Clinical Laboratory Techniques | 1 | 2011 | 89 | 0.090 |
Why?
| | Likelihood Functions | 1 | 2010 | 136 | 0.090 |
Why?
| | Spine | 1 | 2011 | 144 | 0.090 |
Why?
| | Preferred Provider Organizations | 1 | 2009 | 5 | 0.090 |
Why?
| | Respiratory Function Tests | 1 | 2011 | 526 | 0.090 |
Why?
| | Analysis of Variance | 1 | 2012 | 1295 | 0.090 |
Why?
| | Transportation | 1 | 2009 | 42 | 0.090 |
Why?
| | Adolescent | 4 | 2016 | 18483 | 0.080 |
Why?
| | Private Sector | 1 | 2009 | 51 | 0.080 |
Why?
| | Orthopedic Procedures | 1 | 2011 | 225 | 0.080 |
Why?
| | Pain Management | 1 | 2011 | 293 | 0.080 |
Why?
| | Regression Analysis | 2 | 2009 | 984 | 0.080 |
Why?
| | North America | 1 | 2009 | 266 | 0.080 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 4709 | 0.080 |
Why?
| | Electrocardiography | 1 | 2011 | 556 | 0.080 |
Why?
| | Cost-Benefit Analysis | 2 | 2014 | 554 | 0.080 |
Why?
| | Research Design | 1 | 2014 | 969 | 0.080 |
Why?
| | Proportional Hazards Models | 1 | 2011 | 1125 | 0.080 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2012 | 1175 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2010 | 1474 | 0.070 |
Why?
| | Patient Acceptance of Health Care | 1 | 2012 | 687 | 0.070 |
Why?
| | Program Evaluation | 1 | 2010 | 845 | 0.070 |
Why?
| | Colorado | 2 | 2013 | 4196 | 0.070 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2674 | 0.070 |
Why?
| | Peptides | 1 | 2011 | 879 | 0.070 |
Why?
| | Logistic Models | 1 | 2010 | 1901 | 0.070 |
Why?
| | Anti-Allergic Agents | 1 | 2005 | 41 | 0.060 |
Why?
| | Efficiency, Organizational | 1 | 2005 | 126 | 0.060 |
Why?
| | Benchmarking | 1 | 2005 | 172 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 1947 | 0.060 |
Why?
| | Cholesterol, LDL | 1 | 2005 | 317 | 0.060 |
Why?
| | Longitudinal Studies | 1 | 2011 | 2513 | 0.060 |
Why?
| | Histamine H2 Antagonists | 1 | 2004 | 31 | 0.060 |
Why?
| | Hypoglycemic Agents | 1 | 2010 | 1035 | 0.060 |
Why?
| | Hyperlipidemias | 1 | 2003 | 128 | 0.060 |
Why?
| | Patient Compliance | 2 | 2003 | 537 | 0.050 |
Why?
| | Pamphlets | 1 | 2001 | 25 | 0.050 |
Why?
| | Evidence-Based Medicine | 1 | 2005 | 693 | 0.050 |
Why?
| | Health Care Surveys | 1 | 2023 | 546 | 0.050 |
Why?
| | Risk Assessment | 1 | 2010 | 3057 | 0.050 |
Why?
| | Students, Pharmacy | 1 | 2001 | 99 | 0.050 |
Why?
| | Hospitalization | 1 | 2009 | 1785 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 1 | 2011 | 3175 | 0.040 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2003 | 387 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2023 | 4552 | 0.040 |
Why?
| | Recurrence | 1 | 2020 | 975 | 0.040 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3361 | 0.040 |
Why?
| | Registries | 1 | 2023 | 1810 | 0.030 |
Why?
| | Decision Making | 1 | 2001 | 809 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2014 | 103 | 0.030 |
Why?
| | Medical Audit | 1 | 2013 | 75 | 0.030 |
Why?
| | Diabetes Complications | 1 | 2014 | 219 | 0.030 |
Why?
| | Databases, Factual | 1 | 2016 | 1231 | 0.020 |
Why?
| | Child | 2 | 2023 | 19137 | 0.020 |
Why?
| | Prevalence | 1 | 2016 | 2326 | 0.020 |
Why?
| | Comorbidity | 1 | 2014 | 1527 | 0.020 |
Why?
| | Rhinitis, Allergic, Perennial | 1 | 2005 | 23 | 0.020 |
Why?
| | California | 1 | 2005 | 382 | 0.010 |
Why?
| | Child, Preschool | 1 | 2016 | 9493 | 0.010 |
Why?
| | Coronary Disease | 1 | 2003 | 356 | 0.010 |
Why?
| | Risk Factors | 1 | 2003 | 9003 | 0.010 |
Why?
|
|
Nair's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|